|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,954.00 INR | +0.57% |
|
+0.13% | +13.62% |
| 07-21 | South Africa regulator reviews 12 generic semaglutide applications | RE |
| 07-15 | India's Sun Pharma wins South Africa approval to launch generic Ozempic | RE |
| Market Cap | 4,688B 48.41B 42.58B 39.55B 36.38B 68.22B 69.45B 473B 184B 2,287B 182B 178B 7,933B | P/E 2027 * |
35.8x | P/E 2028 * | 30.3x |
|---|---|---|---|---|---|
| Enterprise Value | 4,425B 45.69B 40.19B 37.33B 34.34B 64.39B 65.54B 446B 174B 2,158B 172B 168B 7,488B | EV / Sales 2027 * |
6.76x | EV / Sales 2028 * | 5.97x |
| Free-Float |
44.39% | Yield 2027 * |
0.81% | Yield 2028 * | 0.9% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.57% | ||
| 1 week | +0.13% | ||
| Current month | +4.91% | ||
| 1 month | +4.89% | ||
| 3 months | +17.02% | ||
| 6 months | +19.57% | ||
| Current year | +13.62% |
| 1 week | 1,922.5 |  | 1,966.5 |
| 1 month | 1,855.9 | | 1,966.5 |
| Current year | 1,583.7 | | 1,966.5 |
| 1 year | 1,548 | | 1,966.5 |
| 3 years | 1,068.35 | | 1,966.5 |
| 5 years | 672.55 | | 1,966.5 |
| 10 years | 312 | | 1,966.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.57% | +0.13% | +16.45% | +78.10% | 48.31B | |
| -0.50% | -0.41% | +67.13% | +107.90% | 35.33B | |
| -1.56% | -3.13% | -4.88% | +32.80% | 11.85B | |
| -1.11% | -3.73% | +16.41% | +81.64% | 11.64B | |
| -0.84% | -0.19% | +36.48% | +136.73% | 8.99B | |
| -0.27% | +0.42% | +51.66% | -6.22% | 6.93B | |
| -0.77% | -3.00% | +13.55% | +32.01% | 6.72B | |
| +0.24% | -4.02% | +2.19% | +192.78% | 6.43B | |
| +1.60% | -9.55% | -30.77% | +8.47% | 5.66B | |
| -0.55% | -0.41% | +25.54% | +143.67% | 4.48B | |
| Average | -0.30% | -1.55% | +19.38% | +80.79% | 14.64B | |
| Weighted average by Cap. | -0.18% | -0.90% | +27.54% | +83.75% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.76B 5.94B 5.52B 5.08B 9.52B 9.69B 66.01B 25.75B 319B 25.36B 24.82B 1,107B | 730B 7.53B 6.63B 6.16B 5.66B 10.62B 10.81B 73.62B 28.72B 356B 28.29B 27.68B 1,235B |
| Net income | 132B 1.36B 1.2B 1.12B 1.03B 1.92B 1.96B 13.33B 5.2B 64.46B 5.12B 5.01B 224B | 156B 1.61B 1.42B 1.32B 1.21B 2.27B 2.31B 15.74B 6.14B 76.12B 6.05B 5.92B 264B |
| Net Debt | -263B -2.72B -2.39B -2.22B -2.04B -3.83B -3.9B -26.58B -10.37B -128B -10.21B -9.99B -446B | -329B -3.39B -2.98B -2.77B -2.55B -4.78B -4.87B -33.16B -12.93B -160B -12.74B -12.47B -556B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/07/26 | ₹1,954.00 | +0.57% | 2,057,288 |
| 22/07/26 | ₹1,943.00 | -0.96% | 1,718,430 |
| 21/07/26 | ₹1,961.90 | +0.28% | 1,412,579 |
| 20/07/26 | ₹1,956.40 | +1.23% | 1,676,034 |
| 17/07/26 | ₹1,932.60 | -0.90% | 2,475,664 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
